Dimerix Limited (DXB.AX)
Dimerix Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Fitzroy, VIC, AU. The stock last traded at $0.28, down 3.45% on the session, giving a market capitalisation of $168.1M. Its beta of 0.33 implies it has historically moved less than the broad market.
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
Dimerix Limited is most often compared with the following Healthcare names: